Immix Biopharma Inc
NASDAQ:IMMX
Income Statement
Earnings Waterfall
Immix Biopharma Inc
Income Statement
Immix Biopharma Inc
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(1)
|
(2)
|
(4)
|
(5)
|
(8)
|
(9)
|
(12)
|
(15)
|
(16)
|
(19)
|
(20)
|
(23)
|
(23)
|
(22)
|
(24)
|
(24)
|
|
| Selling, General & Administrative |
(1)
|
(2)
|
(3)
|
(3)
|
(4)
|
(5)
|
(5)
|
(7)
|
(7)
|
(9)
|
(10)
|
(10)
|
(11)
|
(12)
|
(12)
|
(12)
|
|
| Research & Development |
(0)
|
(1)
|
(1)
|
(2)
|
(4)
|
(5)
|
(6)
|
(8)
|
(9)
|
(11)
|
(11)
|
(13)
|
(11)
|
(10)
|
(12)
|
(12)
|
|
| Operating Income |
(1)
N/A
|
(2)
-75%
|
(4)
-66%
|
(5)
-30%
|
(8)
-61%
|
(9)
-14%
|
(12)
-23%
|
(15)
-26%
|
(16)
-11%
|
(19)
-19%
|
(20)
-5%
|
(23)
-14%
|
(23)
+2%
|
(22)
+4%
|
(24)
-9%
|
(24)
-1%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
(23)
|
(22)
|
(22)
|
(22)
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Non-Reccuring Items |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(24)
N/A
|
(24)
0%
|
(26)
-6%
|
(27)
-4%
|
(8)
+70%
|
(9)
-14%
|
(11)
-22%
|
(14)
-25%
|
(16)
-10%
|
(18)
-18%
|
(19)
-4%
|
(22)
-15%
|
(22)
+2%
|
(21)
+4%
|
(23)
-11%
|
(24)
-2%
|
|
| Net Income | |||||||||||||||||
| Tax Provision |
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(24)
|
(24)
|
(26)
|
(27)
|
(8)
|
(9)
|
(11)
|
(14)
|
(16)
|
(18)
|
(19)
|
(22)
|
(22)
|
(21)
|
(23)
|
(24)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(24)
N/A
|
(24)
0%
|
(26)
-6%
|
(27)
-4%
|
(8)
+70%
|
(9)
-14%
|
(11)
-22%
|
(14)
-24%
|
(15)
-9%
|
(18)
-18%
|
(19)
-4%
|
(22)
-15%
|
(22)
+1%
|
(21)
+3%
|
(23)
-11%
|
(24)
-2%
|
|
| EPS (Diluted) |
-3.39
N/A
|
-1.77
+48%
|
-1.87
-6%
|
-1.95
-4%
|
-0.59
+70%
|
-0.67
-14%
|
-0.75
-12%
|
-0.76
-1%
|
-0.89
-17%
|
-0.77
+13%
|
-0.66
+14%
|
-0.74
-12%
|
-0.76
-3%
|
-0.71
+7%
|
-0.78
-10%
|
-0.73
+6%
|
|